Newsletter Subscription

Enter Name and Email

NeuroAct Communication - Newsletter - April 2014


Expertise in Neuropharmacology





Spring News

PhD Examiner at brain imaging center in Lyon

Adrian was external examiner for a PhD candidate at the brain imaging center of the University of Lyon, France (11th December 2013). The thesis work was carried out by Guillaume Becker, in the laboratory of Prof. Luc Zimmer. The thesis was entitled: "New concepts for functional imaging of serotonin 5-HT1A and 5-HT6 receptors during neurodegenerative processes."

Lecture at Pharmacology 2013 meeting in London

Adrian Newman-Tancredi was an invited speaker at the British Pharmacological Society's meeting on Tuesday 17 December. The session was organized by the International Society for Serotonin Research, of which Adrian is European Council member, and presented recent discoveries that bring renewed interest in serotonin receptors as promising targets for treatment of psychiatric and neurological disorders. For further information click here.









Neurolixis Update

European Commission approves Orphan Medicinal Product designation for NLX-101

Neurolixis Inc., of which Adrian Newman-Tancredi, PhD, DSc, is co-founder and Chief Scientific Officer, announced that the European Commission approved its application for Orphan Medicinal Product Designation for NLX-101 in the treatment of Rett syndrome (see European Commission register). Rett syndrome is a rare genetic disorder that affects 1 female in about 10 000 and causes extensive and debilitating symptoms. NLX-101 targets the breathing difficulties that are commonly experienced by Rett syndrome patients. Orphan Medicinal Product designation provides a ten-year period of European Union marketing exclusivity as well as other benefits.

See the full press announcement here.

For further information, Contact.



Supplementary grant awarded by Fox Foundation

Adrian Newman-Tancredi is Principal Investigator of a supplemental grant awarded by the Michael J Fox Foundation. The grant will support investigation of a highly selective serotonin 5-HT1A receptor agonist, NLX-112, in models of Parkinson's Disease. The experiments will be carried out in collaboration with Dr. Andrew McCreary of BrainsOnline (Groningen, Netherlands). 

For further information click here.


Scientific Communication

Just Published:

(click on links to view Abstracts)

Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT1A receptor activation.
Schreiber R, Newman-Tancredi A.
Neurobiol Learn Mem. 2014 Jan 11. pii: S1074-7427(13)00271-2. doi: 10.1016/j.nlm.2013.12.015.

ADN-1184 a monoaminergic ligand with 5-HT6/7 receptor antagonism: pharmacological profile and potential therapeutic utility.
Kołaczkowski M, Mierzejewski P, Bieńkowski P, Wesołowska A, Newman-Tancredi A.

Br J Pharmacol. 2014 Feb;171(4):973-84.

5-HT1A receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function.
Garcia-Garcia AL, Newman-Tancredi A, Leonardo ED. Psychopharmacology (Berl). 2014 Feb; 231(4):623-36.



 NeuroAct Communication advises lifescience companies and funding agencies on neuropharmacology and central nervous system drug discovery programs. 

 NeuroAct Communication is an independent consulting service founded by
Adrian Newman-Tancredi PhD DSc, an experienced pharmaceutical industry professional.

Find out more about Adrian in his Executive Profile